Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Catalyst Biosciences Inc is a biotechnology business based in the US. Catalyst Biosciences shares (CBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Catalyst Biosciences employs 56 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $0.59 |
|---|---|
| 52-week range | $0.58 - $7.55 |
| 50-day moving average | $1.14 |
| 200-day moving average | $3.50 |
| Wall St. target price | $11.67 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-3.06 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.5856 from 2022-01-25
| 1 week (2022-01-15) | N/A |
|---|---|
| 1 month (2021-12-22) | N/A |
| 3 months (2021-10-25) | -82.88% |
| 6 months (2021-07-26) | -86.16% |
| 1 year (2021-01-26) | -90.75% |
|---|---|
| 2 years (2020-01-24) | -91.29% |
| 3 years (2019-01-25) | 7.67 |
| 5 years (2017-01-26) | 2.74% |
Valuing Catalyst Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalyst Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Catalyst Biosciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.02. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Catalyst Biosciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $6.9 million |
|---|---|
| Gross profit TTM | $-40,390,000 |
| Return on assets TTM | -56.76% |
| Return on equity TTM | -111.78% |
| Profit margin | 0% |
| Book value | $1.94 |
| Market capitalisation | $19.8 million |
TTM: trailing 12 months
We're not expecting Catalyst Biosciences to pay a dividend over the next 12 months.
Catalyst Biosciences's shares were split on a 1:15 basis on 12 February 2017. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Catalyst Biosciences shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Catalyst Biosciences shares which in turn could have impacted Catalyst Biosciences's share price.
Over the last 12 months, Catalyst Biosciences's shares have ranged in value from as little as $0.58 up to $7.55. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catalyst Biosciences's is 1.8231. This would suggest that Catalyst Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Catalyst Biosciences, Inc. , a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company engineer proteases to develop improved or novel molecules to treat diseases that result from dysregulation of the complement and coagulation cascades. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously administered engineered coagulation; and Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. The company's pipeline also includes a preclinical program partnered with Biogen International GmbH for dry age-related macular degeneration (AMD); factor I protease for SQ prophylaxis in patients with complement factor I deficiency and C4b-degraders designed to target disorders of the classical complement pathway, as well as other complement programs. The company also develops CB 4332 intended for lifelong prophylactic SQ administration in individuals with CFI deficiency; and CB 2782-PEG, a C3 degrader product candidate in preclinical development for the treatment of dry AMD. It has a strategic research collaboration with Mosaic Biosciences, Inc.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.